<DOC>
	<DOCNO>NCT03016468</DOCNO>
	<brief_summary>This multicenter , single-arm trial evaluate safety transition Selexipag Remodulin® Oral Treprostinil Symptomatic Subjects Pulmonary Arterial Hypertension ( PAH ) . The study include 30 subject approximately 10 clinical trial center . The treatment phase study last approximately 16 week .</brief_summary>
	<brief_title>Safety Transition From Selexipag Remodulin® Then Oral Treprostinil Symptomatic Adult PAH</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<mesh_term>Selexipag</mesh_term>
	<criteria>1 . Subject diagnosis symptomatic idiopathic heritable PAH , PAH associate connective tissue disease , PAH associate HIV infection , PAH associate repaired congenital systemictopulmonary shunt ( least 1 year since repair respect date providing informed consent ) , PAH associate appetite suppressant toxin use . 2 . The subject must classify WHO FC II III Baseline . 3 . The subject receive selexipag treatment WHO Group 1 PAH minimum 90 day Baseline . 4 . Subject need escalation therapy , determine Investigator . 5 . Subject must receive Food Drug Administration ( FDA ) approve PDE5I sGC stimulator and/or ERA current stable dose least 28 day prior Baseline . 1 . The subject receive selexipag disease condition treatment WHO Group 1 PAH . 2 . The subject Baseline 6MWD less 150 meter . 3 . The subject 's Baseline 6MWD decrease 40 % preselexipag baseline . 4 . The subject history ischemic heart disease ( define either symptomatic require antianginal therapy experience document myocardial infarction within previous 6 month Baseline ) , history leave sided myocardial dysfunction evidence PAWP great 15 mmHg leave ventricular ejection fraction le 40 % . 5 . The subject previously treat parenteral prostacyclin oral treprostinil period 90 day . 6 . The subject history 1 follow sign relevant lung disease within 180 day Baseline : 1 . Total lung capacity le 60 % predict normal . 2 . Forced expiratory volume 1 second less 55 % predict normal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Oral Treprostinil</keyword>
	<keyword>Remodulin</keyword>
	<keyword>Selexipag</keyword>
	<keyword>6 Minute Walk Test</keyword>
</DOC>